Key Segments:
By Therapeutic Cell Type
-
T Cells
-
Natural Killer Cells
-
Myeloid Cells
-
Hematopoietic Stem Cells
By Therapeutic Application
-
Hematological Malignancies
-
Solid Tumors
-
Autoimmune Diseases
-
Genetic & Rare Disorders
By In Vivo Cell Engineering Technology
-
Receptor Engineering
-
Gene Editing & Gene Modification
-
Cell Reprogramming
-
Epigenetic Modulation
By Delivery Modality
-
Viral Vector-Based
-
Lipid Nanoparticle-Based
-
Non-Viral Physical Delivery
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
By therapeutic cell type, the T Cells segment dominated the market with approximately 79.40% share in 2025, supported by validated chimeric antigen receptor designs carried over from the ex vivo CAR-T market.
The market includes Gilead Sciences, Legend Biotech, Eli Lilly, AbbVie, AstraZeneca, Bristol Myers Squibb, CRISPR Therapeutics, Umoja Biopharma, Ensoma, Tessera Therapeutics, Sana Biotechnology and CREATE Medicines, among others. These companies compete on delivery chemistry, platform breadth and deal-making speed.
The main opportunities lie in extending validated platforms from oncology into autoimmune disease and inherited blood disorders, and in partnerships between Asia Pacific developers and Western pharmaceutical acquirers seeking lower-cost access to clinical data.
The key growth factor is the willingness of large pharmaceutical companies to acquire clinical-stage in vivo platforms at billion-dollar valuations, reinforced by government research funding aimed at removing apheresis and lymphodepletion from cell therapy manufacturing.
North America dominated the market with approximately 54.70% share in 2025, supported by a concentration of platform developers and acquirers. Asia Pacific is the fastest-growing region with a projected CAGR of 36.90% from 2026 to 2035.